| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2013: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2012: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Outline of Final Research Achievements |
Nicergoline is an ergoline derivative used to treat various symptoms related to cerebrovascular disease. There have been some studies that may support a trial of nicergoline for post-stroke depression, but the exact mechanism of the action is unknown. The aim of this study was to examine the effects of nicergoline on the norepinephrine transporter and serotonin transporter (SET), which are known as intracellular targets of anidepressants.
Nicergoline decreased the [3H]norepinephrine uptake by SK-N-SH cells in a concentration-dependent manner (0.1-10 M). Nicergoline decreased the [3H]serotonin uptake by SET-transfected COS-7 cells in the concentration of 100 M. In the FST, combined treatment with imipramine and nicergoline reduced the immobility time more than the treatment with imipramine alone.
The present findings suggest that nicergoline may decrease neuronal monoamine uptake, which could be useful for the treatment of post-stroke depression.
|
